TY - JOUR
T1 - Thrombolytic Therapy
T2 - Current Status
AU - Fratantoni, Joseph C.
AU - Ness, Paul
AU - Simon, Toby L.
PY - 1975/11/20
Y1 - 1975/11/20
N2 - ALTHOUGH many details of the process of thrombogenesis are unclear, it is generally thought that it involves both platelet activity (adhesion and aggregation) and fibrin formation.1,2 Both processes appear to be active in arterial and venous thrombogenesis, although their relative importance is not certain. In any event, physiologic fibrinolysis is theoretically important in the resolution of both arterial and venous thrombi, and agents which enhance this process may function as thrombolytic agents. Experimental studies dealing with this hypothesis have been extensive and are generally reviewed elsewhere.3,4 More recently, a number of clinical trials have been conducted to evaluate thrombolytic therapy.
AB - ALTHOUGH many details of the process of thrombogenesis are unclear, it is generally thought that it involves both platelet activity (adhesion and aggregation) and fibrin formation.1,2 Both processes appear to be active in arterial and venous thrombogenesis, although their relative importance is not certain. In any event, physiologic fibrinolysis is theoretically important in the resolution of both arterial and venous thrombi, and agents which enhance this process may function as thrombolytic agents. Experimental studies dealing with this hypothesis have been extensive and are generally reviewed elsewhere.3,4 More recently, a number of clinical trials have been conducted to evaluate thrombolytic therapy.
UR - http://www.scopus.com/inward/record.url?scp=0016712497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016712497&partnerID=8YFLogxK
U2 - 10.1056/NEJM197511202932106
DO - 10.1056/NEJM197511202932106
M3 - Review article
C2 - 1178024
AN - SCOPUS:0016712497
SN - 0028-4793
VL - 293
SP - 1073
EP - 1078
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 21
ER -